MFAP4: A candidate biomarker for hepatic and pulmonary fibrosis?

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 33, Issue 1, 2016, Pages 41-50

  Mölleken, Christian ^a   Poschmann, Gereon ^b   Bonella, Francesco ^c   Costabel, Ulrich ^c   Sitek, Barbara ^d   Stühler, Kai ^b   Meyer, Helmut E ^d,e   Schmiegel, Wolff H ^a   Marcussen, Niels ^f   Helmer, Michael ^f   Nielsen, Ole ^f   Hansen, Søren ^g   Schlosser, Anders ^f   Holmskov, Uffe ^f   Sorensen, Grith Lykke ^f  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c RUHRLANDKLINIK   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e LEIBNIZ INSTITUT FÜR ANALYTISCHE WISSENSCHAFTEN ISAS E V   (Germany)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^g Department of Cancer and Inflammation Research ^*  (Denmark)

Author keywords

Biomarkers for pulmonary fibrosis; Extracellular matrix; Fibro genesis; Idiopathic pulmonary fibrosis (IPF); Mouse model of pulmonary fibrosis

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; LACTATE DEHYDROGENASE; MEMBRANE PROTEIN; MICROFIBRILLAR ASSOCIATED GLYCOPROTEIN 4; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; CARRIER PROTEIN; GLYCOPROTEIN; MFAP4 PROTEIN, HUMAN; MFAP4 PROTEIN, MOUSE; SCLEROPROTEIN;

ADULT; AGED; ALLERGIC PNEUMONITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROGENESIS; FIBROSING ALVEOLITIS; HUMAN; LIVER FIBROSIS; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ANIMAL; BLOOD; C57BL MOUSE; DEFICIENCY; IDIOPATHIC PULMONARY FIBROSIS; LIVER CIRRHOSIS;

ADULT; AGED; ANIMALS; BIOMARKERS; CARRIER PROTEINS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84963944144     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. du Bois, RM. Genetic factors in pulmonary fibrotic disorders. Semin Respir Crit Care Med 2006; 27: 581-8.
2. Eickelberg O, Laurent GJ. The quest for the initial lesion in idiopathic pulmonary fibrosis: gene expression differences in IPF fibroblasts. Am J Respir Cell Mol Biol 2010; 42: 1-2.
3. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr., Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
4. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
5. Eickelberg O. Endless healing: TGF-beta, SMADs, and fibrosis. FEBS Lett 2001; 506: 11-4.
6. Yano T, Deterding RR, Nielsen LD, Jacoby C, Shannon JM, Mason RJ. Surfactant protein and CC-10 expression in acute lung injury and in response to keratinocyte growth factor. Chest 1997; 111: 137S- 138S.
7. Guillouzo A. Liver cell models in in vitro toxicology. Environ Health Perspect 1998; 106 Suppl 2: 511-32.
8. Suematsu M, Suzuki H, Delano FA, Schmid-Schonbein GW. The inflammatory aspect of the microcirculation in hypertension: oxidative stress, leukocytes/endothelial interaction, apoptosis. Microcirculation 2002; 9: 259-76.
9. Kuwano K, Hagimoto N, Nakanishi Y. The role of apoptosis in pulmonary fibrosis. Histol Histopathol 2004; 19: 867-81.
10. Ask K, Bonniaud P, Maass K, Eickelberg O, Margetts PJ, Warburton D, Groffen J, Gauldie J, Kolb M. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int J Biochem Cell Biol 2008; 40: 484-95.
11. ten Dijke, P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004; 29: 265-73.
12. Yu H, Konigshoff M, Jayachandran A, Handley D, Seeger W, Kaminski N, Eickelberg O. Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis. FASEB J 2008; 22: 1778-89.
13. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170: 1807-1816.
14. Konigshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, Rose F, Fink L, Seeger W, Schaefer L, Gunther A, Eickelberg O. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 2009; 119: 772-87.
15. Rodriguez-Boulan E, Nelson WJ. Morphogenesis of the polarized epithelial cell phenotype. Science 1989; 245: 718-25.
16. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309: 30-3.
17. Mölleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M, Friedman SL, Tornoe I, Schlosser A, Kloppel G, Schmiegel W, Meyer HE, Holmskov U, Stuhler K. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology 2009; 49: 1257-66.
18. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
19. Lausen M, Lynch N, Schlosser A, Tornoe I, Saekmose SG, Teisner B, Willis AC, Crouch E, Schwaeble W, Holmskov U. Microfibrillar-associated protein 4 is present in lung washings and binds to the col lagen region of lung surfactant protein D. J Biol Chem 1999; 274: 32234-40.
20. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165: 277-304.
21. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004; 31: 1112-20.
22. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, Cascade PN, Whyte RI, Lynch JP 3rd, Toews G. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169: 977-83.
23. Breitkopf K, Godoy P, Ciuclan L, Singer MV, Dooley S. TGF-beta/Smad signaling in the injured liver. Z Gastroenterol 2006; 44: 57-66.
24. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, Iredale JP. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56-65.
25. Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005; 10: 927-39.
26. Kisseleva T, Brenner DA. Fibrogenesis of parenchymal organs. Proc Am Thorac Soc 2008; 5: 338-42.
27. Strieter RM, Gomperts BN, Keane MP. The role of CXC chemokines in pulmonary fibrosis. J Clin Invest 2007; 117: 549-56.
28. Kuwano K, Hagimoto N, Kawasaki M, Yatomi T, Nakamura N, Nagata S, Suda T, Kunitake R, Maeyama T, Miyazaki H, Hara N. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999; 104: 13-9.
29. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-51.
30. Selman M, Pardo A. Idiopathic pulmonary fibrosis: An epithelial/fibroblastic cross-talk disorder. Respir Res 2002; 3: 3.
31. Schlosser A, Thomsen T, Shipley JM, Hein PW, Brasch F, Tornøe I, Nielsen O, Skjødt K, Palaniyar N, Steinhilber W, McCormack FX, Holmskov U. Microfibrillar-associated protein 4 binds to surfactant protein A (SP-A) and colocalizes with SP-A in the extracellular matrix of the lung. Scand J Immunol. 2006 Aug; 64 (2): 104-16.
32. Casey J, Kaplan J, Atochina-Vasserman EN, Gow AJ, Kadire H, Tomer Y, Fisher JH, Corbel S, Boichot ME, Lagente V. Role of gelatinases MMP-2 and MMP-9 intissue remodeling following acute lung injury. Braz J Med Biol Res 2000; 33:749-54.
33. Hawgood S, Savani RC, Beers MF. Alveolar surfactant protein D contentmodulates bleomycin-induced lung injury. Am J Respir Crit Care Med 2005; 172: 869-77.
34. Walters DM, Kleeberger SR. Mouse Models of Bleomycin-Induced Pulmonary Fibrosis. Curr Protoc Pharmacol 2008; 40: 17.
35. Schlosser A. Microfibrillar-Associated Protein 4 (MFAP4) and FReD-1 Two members of The fibrinogen somain superfamily In Institute of Medical Biology. University ofSouthern Denmark, Odense. 2004: 64.
36. Garantziotis S, Schwartz DA. Host-environment interactions in pulmonary fibrosis. Semin Respir Crit Care Med 2006; 27: 574-80.
37. Khalil N, Churg A, Muller N, O'Connor R. Environmental, inhaled and ingested causes of pulmonary fibrosis. Toxicol Pathol 2007; 35: 86-96.
38. Wulf-Johansson H, Lock Johansson S, Schlosser A. Trommelholt Holm A, Melholt Rasmussen L, Mickley H, Diederichsen ACP, Munkholm H, Svenstrup Poulsen T, Tornøe I, Nielsen V, Marcussen N, Vestbo J, Gjørup Sækmose S, Holmskov U, Sorensen G.L. Localization of Microfibrillar-Associated Protein 4 (MFAP4) in Human Tissues: Clinical Evaluation of Serum MFAP4 and Its Association with Various Cardiovascular Conditions. PLoS One 2013; 8 (12): e82243.